XML 57 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative and Other Arrangements - Collaborative Arrangements Narrative (Details)
€ / shares in Units, € in Millions, shares in Millions, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 09, 2019
USD ($)
shares
Nov. 06, 2019
€ / shares
shares
Aug. 23, 2019
USD ($)
shares
Aug. 23, 2019
€ / shares
Jul. 19, 2018
USD ($)
Jul. 19, 2018
EUR (€)
Jan. 19, 2016
USD ($)
shares
Jan. 19, 2016
€ / shares
Collaborative Arrangements                              
Prepaid and other current assets   $ 1,606     $ 1,440 $ 1,606                  
Research and development expenses         9,106 5,018 $ 3,734                
Goodwill   4,117     4,117 4,117                  
Cost of goods sold         $ 4,675 4,853 4,371                
Upfront collaboration and licensing expense [Member]                              
Collaborative Arrangements                              
Research and development expenses     $ 3,920                        
Gadeta [Member]                              
Collaborative Arrangements                              
Collaborative Arrangement-Potential Option Payout Upon Exercise | €                         € 300    
Indefinite-lived Intangible Assets Acquired       $ 117                      
Noncontrolling Interest in Variable Interest Entity                       $ 82      
Goodwill                       $ 0      
Janssen Pharmaceuticals [Member]                              
Collaborative Arrangements                              
Purchase price of goods less specified amount, maximum percentage         30.00%                    
Cost of goods sold         $ 574 608 561                
Japan Tobacco [Member]                              
Collaborative Arrangements                              
Finite-lived Intangible Assets Acquired           550                  
Prepaid and other current assets   9       $ 9                  
Finite-Lived Intangible Asset, Useful Life           9 years                  
Royalty Expense         358 $ 452 400                
Initial Consideration for Acquisition of Rights to Market and Distribute Certain Products in Japan   559                          
Payments to Acquire Management Contract Rights   $ 194     365                    
Galapagos [Member]                              
Collaborative Arrangements                              
Standstill Restricting Term 10 years                            
Available-for-sale Securities, Equity Securities, Noncurrent               $ 586   $ 1,130       $ 357  
Share Price | € / shares                     € 140.59       € 58
Investment Owned, Balance, Shares | shares               16.7 2.6 6.8       6.8  
Class of Warrant or Right, Exercise Price of Warrants or Rights | € / shares                 € 140.59            
Equity Method Investment, Ownership Percentage               25.80%              
Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement                   29.90%          
Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement                   20.10%          
Potential Milestone for GLPG-1972 after Option Exercise         640         $ 750          
Potential Future Sales-based Milestone         $ 600                    
Potential Future Tiered Royalty Payment Low-end         20.00%                    
Potential Future Tiered Royalty Payment High-end         30.00%                    
Payment for License, Option Rights and Equity Investments Upon Closing $ 5,050                            
Issuance discount                   63          
Potential Milestone Payment Upon Marketing Approval GLPG-1690                   325          
Potential Option Exercise Fee for GLPG-1972                   250          
Potential Option Exercise Fee Per Program                   $ 150          
Potential Sales Based Tiered Royalty Low-end                   20.00%          
Potential Sales Based Tiered Royalties High-end                   24.00%          
Bristol-Myers-Squibb [Member]                              
Collaborative Arrangements                              
Cost of goods sold         $ 58 198                  
Other Collaboration Arrangements [Member]                              
Collaborative Arrangements                              
Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant         331 278                  
Cash Outflows Related to Other Collaboration Arrangements That Are Not Individually Significant         $ 467 $ 474 $ 0